Cochrane · systematic review · CD000203
Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
Alabed, S, Latifeh, Y, Mohammad, HA, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 4 · 66.7%Low 1 · 16.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyGABA DRUGS for antipsychotic‐induced tardive dyskinesia
Population: patients with antipsychotic‐induced TD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: Not improved to a clinically important extent | RR 0.83 [0.74, 0.92] | 3 studies · 258 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration of symptoms | RR 1.9 [0.7, 5.16] | 5 studies · 136 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events | RR 4.54 | 9 studies · 284 participants | Very low Downgraded: risk of bias, imprecision |
Mental state: Deterioration | RR 2.65 [0.71, 9.86] | 6 studies · 121 participants | Very low Downgraded: risk of bias, imprecision |
Acceptability of treatment: Leaving the study early | RR 1.47 [0.69, 3.15] | 6 studies · 218 participants | Very low Downgraded: risk of bias, imprecision |
Social confidence, social inclusion, social networks, or personalised quality of life measures | no estimate extracted | NR | No studies |
GABA DRUGS for neuroleptic‐induced tardive dyskinesia
Population: patients with neuroleptic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: 1. Not improved to a clinically important extent ‐ baclofen | RR 0.78 [0.46, 1.31] | 1 study · 33 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 1. Not improved to a clinically important extent ‐ sodium valproate | RR 0.94 [0.8, 1.11] | 1 study · 62 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 2. Not any improvement ‐ baclofen | RR 1.01 [0.37, 2.74] | 2 studies · 43 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 2. Not any improvement ‐ sodium valproate | RR 0.72 [0.35, 1.46] | 2 studies · 94 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 5. Deterioration of symptoms ‐ baclofen | RR 1.08 [0.17, 6.78] | 3 studies · 61 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 5. Deterioration of symptoms ‐ sodium valproate | RR 2.64 [0.58, 12.06] | 1 study · 62 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects ‐ sedation/drowsiness (baclofen, sodium valproate) | RR 2.12 [0.83, 5.39] | 3 studies · 113 participants | Low Downgraded: risk of bias, imprecision |